Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptorum Group Limited - Class A Ordinary Shares (NQ:APM)

1.070 +0.010 (+0.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptorum Group Limited - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers TCR2 Therapeutics (NASDAQ:TCRR) s... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Aptorum Group (NASDAQ:APM) stock increased by 32.8% to $1.62 during Thursday's regular session. Aptorum Group's stock is trading at a volume of 86.4... 
Via Benzinga
News headline image
Stocks Roar Back to Life Despite Alarming Jobs Data ↗
Stocks are staging a massive comeback today, with the Dow Jones Industrial Average last seen up 428 points midday. Both the S&P 500 Index and Nasdaq Composite are sporting solid midday gains as well. 
Via Talk Markets
News headline image
Aptorum Shares Rise After FDA Orphan Drug Tag For Repurposed Compound For Pediatric Cancer ↗
The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma. Aptorum... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Gainers Baudax Bio (NASDAQ:BXRX) stock rose 32.2% to $0.26 during Thursday's pre-market session. The company's market cap stands at $21.9 million. Aptorum Group (... 
Via Benzinga
News headline image
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Interview to Air on Bloomberg U.S.
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum To Start Testing SACT-1 In Neuroblastoma Patients ↗
The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is... 
Via Benzinga
News headline image
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate ↗
Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus. Specifically,... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Celldex Therapeutics (NASDAQ:CLDX) stock rose 41.93% to $46.0 during Monday's pre-market session. The company's market cap stands at $1.8 billion. 180 Life... 
Via Benzinga
News headline image
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
From Aptorum Group Limited
Via Business Wire
News headline image
Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
From Aptorum Group Limited
Via Business Wire
News headline image
58 Biggest Movers From Friday ↗
Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.... 
Via Benzinga
News headline image
Aptorum Group CEO Subscribed Shares In The Company
From Aptorum Group Limited
Via Business Wire
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Flanigan's Enterprises, Inc. (NYSE: BDL) shares surged 40.6% to close at $34.90 on Tuesday after the company reported results for the 13 weeks and the 26 weeks ended... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 43.23% to $2.65 during Tuesday's regular session. As of 12:30 EST, Pieris Pharmaceuticals's... 
Via Benzinga
News headline image
42 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 28.4% to $10.17 following reports indicating equipment billings increased 50% in April compared to the prior year's... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 101.34% to $12.0 during Monday's regular session. As of 12:30 EST, this security is trading at a volume of 17.5... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge ↗
Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
52 Biggest Movers From Yesterday ↗
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares climbed 72% to close at $10.25 on Monday after the company reported the FDA approval of IND application for CpG-STAT3siRNA,... 
Via Benzinga
News headline image
35 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Scopus BioPharma Inc. (NASDAQ: SCPS) shares jumped 123.7% to $13.33 after the company reported the FDA approval of IND application for CpG-STAT3siRNA, its distinctive... 
Via Benzinga
News headline image
Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study ↗
Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.